[an error occurred while processing this directive]
Cardiovascular disease and cardiac biomarkers
Partner with the pioneers for earlier, more confident clinical decision making.
Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD).1 The increasing incidence and high cost of care of CVDs demands a global approach to prevention, early detection & treatment, and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support rapid and accurate diagnosis, especially in acute cases where every minute counts.2-5
Roche has been the pioneer in in vitro diagnostic tests for CVD decision making for over 30 years. As a market leader in cardiac biomarkers,6 Roche offers diagnostic tests for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF) to support early clinical decision making, improved patient management, and increased efficiency & cost management.
Roche NT-proBNP test:
The gold standard heart failure biomarker.7
Acute Coronary Syndrome
Roche Troponin T-high sensitive:
Triage over 75% of chest pain patients in as little as 1 hour.8-10
Roche CARDIAC POC Troponin T:
Faster triaging of patients with suspected acute myocardial infarction in pre-hospital care and emergency room.11,12
Personalised bleeding-risk prediction for your AF patients.13